Surface-Modified Ta3N5 Photoanodes for Sunlight-Driven Overall Water Splitting by Photoelectrochemical Cells

The development of visible-light-responsive semiconductor-based photoelectrodes is a prerequisite for the construction of efficient photoelectrochemical (PEC) cells for solar water splitting. Surface modification with an electrocatalyst on the photoelectrode is effective for maximizing the water splitting efficiency of the PEC cell. Herein, we investigate the effects of surface modification of Ta3N5 photoanodes with electrocatalysts consisting of Ni, Fe, and Co oxides, and their mixture, on the PEC oxygen evolution reaction (OER) performance. Among the investigated samples, NiFeOx-modified Ta3N5 (NiFeOx/Ta3N5) photoanodes showed the lowest onset potential for OER. A PEC cell with a parallel configuration consisting of a NiFeOx/Ta3N5 photoanode and an Al-doped La5Ti2Cu0.9Ag0.1S5O7 (LTCA:Al) photocathode exhibited stoichiometric hydrogen and oxygen generation from water splitting, without any external bias voltage. The solar-to-hydrogen energy conversion efficiency (STH) of this cell for water splitting was found to be 0.2% at 1 min after the start of the reaction. In addition, water splitting by a PEC cell with a tandem configuration incorporating a NiFeOx/Ta3N5 transparent photoanode prepared on a quartz insulating substrate as a front-side electrode and a LTCA:Al photocathode as a back side electrode was demonstrated, and the STH was found to be 0.04% at the initial stage of the reaction

Anserine, a Histidine-Containing Dipeptide, Suppresses Pressure Overload-Induced Systolic Dysfunction by Inhibiting Histone Acetyltransferase Activity of p300 in Mice

Anserine, an imidazole dipeptide, is present in the muscles of birds and fish and has various bioactivities, such as anti-inflammatory and anti-fatigue effects. However, the effect of anserine on the development of heart failure remains unknown. We cultured primary cardiomyocytes with 0.03 mM to 10 mM anserine and stimulated them with phenylephrine for 48 h. Anserine significantly suppressed the phenylephrine-induced increases in cardiomyocyte hypertrophy, ANF and BNP mRNA levels, and histone H3K9 acetylation. An in vitro histone acetyltransferase (HAT) assay showed that anserine directly suppressed p300-HAT activity with an IC50 of 1.87 mM. Subsequently, 8-week-old male C57BL/6J mice were subjected to transverse aortic constriction (TAC) and were randomly assigned to receive daily oral treatment with anserine-containing material, Marine Active® (60 or 200 mg/kg anserine) or vehicle for 8 weeks. Echocardiography revealed that anserine 200 mg/kg significantly prevented the TAC-induced increase in left ventricular posterior wall thickness and the decrease in left ventricular fractional shortening. Moreover, anserine significantly suppressed the TAC-induced acetylation of histone H3K9. These results indicate that anserine suppresses TAC-induced systolic dysfunction, at least in part, by inhibiting p300-HAT activity. Anserine may be used as a pharmacological agent for human heart failure therapy